Fiscal year revenues increased 4-fold and licensed production
space doubled year over year
SMITHS FALLS, ON, June 27, 2016 /CNW/ - Canopy Growth Corporation
("Canopy Growth" or "the Company") (TSX.V: CGC) today released its
financial results for the fourth quarter and fiscal year 2016 ended
March 31, 2016. All financial
information in this press release is reported in Canadian dollars,
unless otherwise indicated.
Consolidated financial results include the accounts of the
Company and its wholly-owned subsidiaries Tweed Inc. ("Tweed"),
Tweed Farms Inc. ("Tweed Farms") and Bedrocan Canada Inc.
("Bedrocan Canada").
Fourth Quarter Fiscal 2016 Highlights
- Revenues of $5.0 million,
representing a greater than 300% increase over the three month
period ended March 31, 2015 and a 45%
increase over Q3, fiscal year 2016
- Sale of Tweed 10:1 Cannabis Oil began on February 25, 2016
- Supported two Canadian licensed producers through the sale of
wholesale product during the fourth quarter
- Over 11,000 registered patients at March
31, 2016 compared to 2,800 at March 31, 2015, and
compared to over 8,200 at December 31,
2015, and greater than 16,000 as of today's date
- Tweed entered into a business partnership with entertainment
and cannabis icon, Snoop Dogg
- Tweed Farms' full 375,000 ft.2 facility licensed to
produce, possess and ship dried marijuana
- Bedrocan launches True Compassionate Pricing program,
all six standardized Bedrocan varieties priced at $5.00 per gram for all clients
Fiscal Year 2016 Highlights
- Revenues of $12.7 million,
representing a greater than 430% increase over the fiscal year
ended March 31, 2015
- Acquired Licensed Producer Bedrocan Canada
- Total licensed production space more than doubled to greater
than 550,000 sq. ft.
- Acquired Licensed Producer applicant MedCannAccess and
introduced industry first in-person service through Tweed Main
Street locations
- Cash position of $15.4 million at
March 31, 2016
Subsequent to Fourth Quarter and Fiscal Year
2016
- Completed $11.5 million bought
deal
- Announced partnership with AusCann Group Holdings Ltd. of
Australia to work together in the
Australian and International markets
- Received conditional approval to list common shares on the
Toronto Stock Exchange. Listing anticipated Q2 2017
"Fiscal 2016 was another year of dramatic change and growth in
our business," said Bruce Linton,
Chairman & CEO, Canopy Growth. "Investments made across our
business, including in our production capacity, in the
diversification of our product offering and in our award winning
customer service, helped deliver a four-fold increase in revenue, a
three-fold increase in registered patients and doubled our licensed
production space."
Added Linton "With the prospect of a legal recreational
marijuana market in Canada on the
horizon and many exciting international business opportunities, we
are committed to building on our strong start. We will
continue to make prudent investments in our business to increase
our market share, diversify our product offering, grow our
production capacity in Canada,
vertically integrate up the value chain of permissible products and
drive international growth."
Fourth Quarter and Fiscal Year 2016 Revenue
Review
Revenue for the fourth quarter was $5.0 million compared to
revenue of $1.2 million in the three
months ended March 31, 2015 and
$3.5 million for the third quarter of
fiscal year 2016.
Revenues for the twelve month fiscal year ended March 31, 2016 were $12.7
million. In comparison, revenues in the fifteen month
period ended March 31, 2015 were
$2.4 million.
Fourth Quarter and Fiscal Year 2016 Product Sales
Review
In the fourth quarter of fiscal year 2016, the Company sold
approximately 700 kilograms and kilogram equivalents at an average
price of $7.16 per gram. In the three month period ended
March 31, 2015, last year,
approximately 167 kilograms were sold at an average price
of $7.24 per gram.
Approximately 1,700 kilograms and kilogram equivalents were sold
in the fiscal year ended March 31,
2016, representing a greater than 400% increase over the
prior fiscal year.
Fourth Quarter and Fiscal Year 2016 Gross Margin
Review
The gross margin, including the unrealized gain on changes in
fair value of biological assets, in accordance with IFRS,
was $2.7 million, or 53% of sales, for the three-month period
ended March 31, 2016. In the comparison period last
year, the gross margin on the same basis was $2.4 million or 197% of sales.
In the twelve month period ended March
31, 2016, the gross margin, inclusive of the unrealized gain
on changes in fair value of biological assets was $19.0 million or 150% of sales, as compared to
$2.8 million, or 119% of sales during
the fifteen month period ended March
31, 2015.
Fourth Quarter and Fiscal Year 2016 Adjusted
Product Contribution Review
The Company's "Adjusted Product Contribution"1 is a
Non-GAAP metric used by management which adjusts the reported gross
margin by excluding the fair value measurements as required by IFRS
and measures the cost of sales for the grams actually sold in the
period. Management believes this measure provides useful
information as it reflects the gross margin based on the Company's
weighted average cost per gram from seed to sale against the grams
sold.
The Adjusted Product Contribution in the fourth quarter of
fiscal 2016 was $3.2 million, or
63% of sales. The Adjusted Product Contribution in the twelve
month period ended March 31, 2016 was
$8.1 million, or 64% of sales.
Fourth Quarter and Fiscal Year 2016 Operating Expense
Review
For the three-month period ended March 31, 2016, sales and
marketing expenses were $2.4 million (three months
ended March 31, 2015 - $0.7 million).
In the twelve month fiscal year ended March 31, 2016, sales and marketing expenses
were $5.7 million. In comparison, in the fifteen month period
ended March 31, 2015, these expenses
were $2.7 million.
The increase in sales and marketing expenses in the three and
twelve month periods ending March 31,
2016 over the comparison periods was invested in refreshing
Bedrocan Canada post-acquisition, launching Tweed's customer
engagement locations and continuing to position the Tweed brand in
preparation for a non-medical market.
General and Administrative ("G&A") expenses were $2.6
million in the three-month period ended March 31, 2016 compared to $1.5 million in the same period last year.
In the twelve month period ended March
31, 2016, G&A expenses were $8.2 million. In
comparison, in the fifteen month period ended March 31, 2015, G&A expenses were
$4.9 million.
The increase in G&A expenses over the comparison periods
last year reflects the Company's growth from the early start-up of
last year, building commercial capacity and capability as a public
company and meeting compliance requirements with Health
Canada.
Fourth Quarter and Fiscal Year 2016 Earnings
Review
The Company reported a net loss of $5.1
million or $0.05 per basic and diluted share for the
fourth quarter ended March 31, 2016,
compared to a net loss of $0.4 million or $0.01 per basic and diluted share in the
comparison period last year.
For the twelve months ended March 31,
2016, the net loss amounted to $3.5 million or $0.05 per basic and diluted share, compared to a
net loss of $9.3 million or
$0.29 per basic and diluted share in
the fifteen months ended March 31,
2015. The net loss was inclusive of the non-cash unrealized
gain on changes in fair value of biological assets described
above.
Fourth Quarter and Fiscal Year 2016 Balance
Sheet and Cash Flow Review
At March 31, 2016, the Company's
cash, comprised of cash and cash equivalents totalled $15.4 million, representing a decrease of
$9.0 million from March 31, 2015. The decrease is attributable to
$12.4 million used to fund
operations, investments in facility enhancements totalling
$13.1 million, and $2.1 million used to repay a loan, partially
offset by net proceeds from financings, including the "bought deal"
common share offering in the third quarter of fiscal year 2016 and
the exercise of warrants and options, together totalling
$20.6 million. Investments
in facility enhancements include the build out of our Tweed Farms
facility and improvements at our Tweed facility, in part required
for the production of cannabis oil extracts and refinements to
production processes.
The Audited Consolidated Financial Statements and Management's
Discussion and Analysis documents have been filed with SEDAR and
are available on www.sedar.com. The basis of financial
reporting in the Unaudited Condensed Interim Consolidated Financial
Statements and Management's Discussion and Analysis documents has
been revised to thousands of Canadian dollars, unless otherwise
indicated.
Subsequent Events
Bought Deal Financing
On April 15, 2016, the Company
announced that it had closed its previously announced short-form
prospectus offering, on a bought deal basis, including the exercise
in full of the underwriters' over-allotment option. A total of
5,002,500 common shares in the capital of the Company were sold at
a price of $2.30 per share, for
aggregate gross proceeds of $11,505,750 (the "Offering"). The Offering
was underwritten by a syndicate of underwriters led by Dundee
Securities Ltd and including GMP Securities L.P.
Canopy Growth and AusCann Group Holdings Ltd. Partnership
Canopy Growth announced a partnership with AusCann Group
Holdings Ltd. ("AusCann"), an early leader in the nascent
Australian medical cannabis industry, in which Canopy Growth will
offer the expertise of Tweed and Tweed Farms in a number of areas
including production, quality assurance and operations, and provide
strategic advisory services to AusCann in exchange for an initial
15% ownership stake in AusCann, as well as future options.
AusCann and Canopy Growth will also aim to work together in
Australian and international markets in a preferential but
non-exclusive arrangement.
Canopy Growth Corporation Received Conditional Approval from the
TSX
On June 8, 2016, the Company
announced it had received conditional approval from the Toronto
Stock Exchange (TSX) to list its common shares once it had
satisfied certain conditions. Canopy Growth will be the first
cannabis producer to list on Canada's most prestigious securities exchange.
CGC expects to meet all conditions of approval and commence trading
on the TSX in the second quarter of fiscal year 2017, the
three-month period ending September 30,
2016.
Note 1: The Adjusted Product Contribution is a non-GAAP
financial measure that does not have any standardized meaning
prescribed by IFRS and may not be comparable to similar measures
presented by other companies. The Adjusted Product
Contribution is reconciled and explained in Management's Discussion
& Analysis under "Adjusted Product Contribution (Non-GAAP
Measure)", a copy of which has been filed today
on www.sedar.com.
Conference Call Details
Canopy Growth will host a conference call and audio webcast with
Bruce Linton, CEO and Tim Saunders, CFO at 8:30 AM Eastern Time,
June 27, 2016.
Webcast Information
A live audio webcast will be available at:
http://event.on24.com/r.htm?e=1169137&s=1&k=9465B1E57BBFDE8C19CCC91D5134D10D
Calling Information
Toll Free Dial-In Number: 1-888-231-8191
International Dial-In Number (647) 427-7450
Conference ID: 86544060
Replay Information
A replay of the call will be accessible by telephone until
11:59 PM ET on July 18, 2016.
Toll Free Dial-in Number: 1-855-859-2056
Replay Password: 86544060
About Canopy Growth Corporation
Canopy Growth is a
world-leading diversified cannabis company, offering diverse brands
and curated cannabis strain varieties in dried and oil extract
forms. Through its wholly‑owned subsidiaries, Tweed, Tweed
Farms, and Bedrocan Canada, Canopy Growth operates three
state-of-the-art production facilities with over half a million
square feet of indoor and greenhouse production capacity.
Canopy Growth has established partnerships with leading sector
names in Canada and abroad.
For more information, www.canopygrowth.com.
Notice Regarding Forward Looking Statements
This
news release contains forward-looking statements. Often, but not
always, forward-looking statements can be identified by the use of
words such as "plans", "expects" or "does not expect", "is
expected", "estimates", "intends", "anticipates" or "does not
anticipate", or "believes", or variations of such words and phrases
or state that certain actions, events or results "may", "could",
"would", "might" or "will" be taken, occur or be achieved.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of Canopy Growth Corporation, Tweed
Inc., Tweed Farms Inc. or Bedrocan Canada Inc. to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Examples of
such statements include future operational and production capacity,
the impact of enhanced infrastructure and production capabilities,
and forecasted available product selection. The
forward-looking statements included in this news release are made
as of the date of this news release and Canopy Growth Corp. does
not undertake an obligation to publicly update such forward-looking
statements to reflect new information, subsequent events or
otherwise unless required by applicable securities legislation.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this
release.
|
|
|
|
|
|
|
|
|
Canopy Growth
Corporation
|
|
|
|
|
|
|
|
|
Consolidated
statements of net loss and comprehensive loss
|
|
|
|
|
|
|
for the three months
and year ended March 31, 2016
|
|
|
|
|
|
|
|
|
and the three months
and fifteen-month period ended March 31, 2015
|
|
|
|
|
|
|
(Expressed in CDN
$000's except per share amounts)
|
|
|
|
|
|
|
|
|
|
|
Three months
ended
|
|
Period
ended
|
|
|
March
31,
|
|
March 31,
|
|
March
31,
|
|
March 31,
|
|
|
2016
|
|
2015
|
|
2016
|
|
2015
|
|
|
|
|
|
|
(12
months)
|
|
(15
months)
|
|
|
|
|
|
|
|
|
|
Revenue
|
$
|
5,042
|
$
|
1,226
|
$
|
12,699
|
$
|
2,371
|
|
|
|
|
|
|
|
|
|
Unrealized gain on
changes in fair value of biological assets
|
|
(12,037)
|
|
(7,711)
|
|
(38,805)
|
|
(8,576)
|
Inventory expensed to
cost of sales
|
|
4,842
|
|
1,225
|
|
12,796
|
|
2,400
|
Production
costs
|
|
9,549
|
|
5,300
|
|
19,722
|
|
5,721
|
Cost of sales
(recovery), net of the unrealized gain on changes in fair value of
biological assets
|
|
2,354
|
|
(1,186)
|
|
(6,287)
|
|
(455)
|
Gross margin,
including the unrealized gain on changes in fair value of
biological assets
|
|
2,688
|
|
2,412
|
|
18,986
|
|
2,826
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales and
marketing
|
|
2,401
|
|
691
|
|
5,653
|
|
2,685
|
Research and
development
|
|
281
|
|
107
|
|
721
|
|
267
|
General and
administration
|
|
2,558
|
|
1,539
|
|
8,177
|
|
4,875
|
Share of loss in
equity investments
|
|
276
|
|
-
|
|
276
|
|
-
|
Acquisition
costs
|
|
-
|
|
-
|
|
1,155
|
|
-
|
Share-based
compensation expense
|
|
1,003
|
|
320
|
|
3,110
|
|
1,559
|
Share-based
compensation expense - Tweed Farms acquisition
|
|
387
|
|
-
|
|
387
|
|
1,000
|
Depreciation and
amortization
|
|
781
|
|
224
|
|
2,256
|
|
646
|
|
|
7,687
|
|
2,880
|
|
21,735
|
|
11,032
|
Loss from
operations
|
|
(4,999)
|
|
(469)
|
|
(2,749)
|
|
(8,206)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
(expense), net
|
|
(29)
|
|
(15)
|
|
(140)
|
|
51
|
(Increase) decrease
in fair value of acquisiton consideration related
liabilities
|
|
260
|
|
-
|
|
(481)
|
|
-
|
Reverse acquisition
transaction costs
|
|
-
|
|
68
|
|
-
|
|
(225)
|
Listing
expense
|
|
-
|
|
-
|
|
-
|
|
(966)
|
|
|
231
|
|
54
|
|
(621)
|
|
(1,140)
|
Net loss and
comprehensive loss before income taxes
|
|
(4,768)
|
|
(415)
|
|
(3,370)
|
|
(9,346)
|
|
|
|
|
|
|
|
|
|
Income tax
expense
|
|
(354)
|
|
-
|
|
(126)
|
|
-
|
Net loss and
comprehensive loss after income taxes
|
$
|
(5,122)
|
$
|
(415)
|
$
|
(3,496)
|
$
|
(9,346)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share,
basic and diluted:
|
$
|
(0.05)
|
$
|
(0.01)
|
$
|
(0.05)
|
$
|
(0.29)
|
|
|
|
|
|
|
|
|
|
Weighted average
number of outstanding common shares:
|
|
|
|
|
|
|
|
|
Basic and
diluted
|
|
98,529,186
|
|
42,142,658
|
|
77,023,935
|
|
32,181,868
|
|
|
|
|
|
|
|
|
|
Canopy Growth
Corporation
|
|
|
Consolidated
statements of financial position
|
|
|
as at March 31, 2016
and March 31, 2015
|
|
|
(Expressed in CDN
$000's)
|
|
|
|
|
|
|
|
March
31,
|
|
March 31,
|
|
|
|
2016
|
|
2015
|
|
|
|
|
|
|
Assets
|
|
|
|
|
|
Current
assets
|
|
|
|
|
|
Cash and cash
equivalents
|
$
|
15,397
|
$
|
21,446
|
Restricted
short-term investment
|
|
-
|
|
10
|
Accounts
receivable, net
|
|
1,110
|
|
342
|
HST
recoverable
|
|
|
376
|
|
431
|
Biological
assets
|
|
|
5,321
|
|
2,028
|
Inventory
|
|
|
22,153
|
|
4,355
|
Prepaid
expenses and other assets
|
|
489
|
|
764
|
|
|
|
44,846
|
|
29,376
|
|
|
|
|
|
|
Property, plant and
equipment
|
|
44,581
|
|
17,745
|
Assets in
process
|
|
|
403
|
|
615
|
Restricted
investment
|
|
|
246
|
|
-
|
Goodwill
|
|
|
20,867
|
|
-
|
Other intangible
assets
|
|
|
31,861
|
|
38
|
Other
assets
|
|
|
557
|
|
-
|
|
|
$
|
143,361
|
$
|
47,774
|
|
|
|
|
|
|
Liabilities
|
|
|
|
|
|
Current
liabilities
|
|
|
|
|
|
Accounts
payable and accrued liabilities
|
$
|
6,107
|
$
|
4,278
|
Deferred
revenue
|
|
|
533
|
|
-
|
Current
portion of long-term debt
|
|
553
|
|
247
|
|
|
|
7,193
|
|
4,525
|
Long-term
debt
|
|
|
3,469
|
|
1,669
|
Acquisition
consideration related liabilities
|
|
1,258
|
|
-
|
Deferred tax
liability
|
|
|
7,413
|
|
-
|
Other
long-term liabilities
|
|
243
|
|
171
|
|
|
|
19,576
|
|
6,365
|
|
|
|
|
|
|
Shareholders'
equity
|
|
|
|
|
|
Share
capital
|
|
|
131,080
|
|
49,826
|
Share-based
reserve
|
|
|
5,804
|
|
1,724
|
Warrants
|
|
|
676
|
|
138
|
Deficit
|
|
|
(13,775)
|
|
(10,279)
|
|
|
|
123,785
|
|
41,409
|
|
|
$
|
143,361
|
$
|
47,774
|
|
|
|
|
|
|
Canopy Growth
Corporation
|
|
|
|
|
Consolidated
statements of cash flows
|
|
|
|
|
for the year ended
March 31, 2016
|
|
|
|
|
and the fifteen-month
period ended March 31, 2015
|
|
|
(Expressed in CDN
$000's)
|
|
|
|
|
|
|
March
31,
|
|
March 31,
|
|
|
2016
|
|
2015
|
|
|
|
|
(15
months)
|
Net inflow (outflow)
of cash related to the following activities:
|
|
|
|
|
|
|
|
|
|
Operating
|
|
|
|
|
Net loss
|
$
|
(3,496)
|
|
(9,346)
|
Items not affecting cash:
|
|
|
|
|
Depreciation of
property, plant and equipment
|
|
2,079
|
|
634
|
Amortization of
intangible assets
|
|
177
|
|
13
|
Share of loss in
equity investments
|
|
276
|
|
-
|
Unrealized gain on
change in fair value of biological assets
|
|
(38,805)
|
|
(8,575)
|
Share-based
compensation
|
|
3,678
|
|
2,559
|
Income tax
expense
|
|
126
|
|
-
|
Decrease in fair value
of acquisition consideration related liabilities
|
481
|
|
-
|
Issuance of shares per
LBC agreement
|
|
350
|
|
-
|
Listing
expense
|
|
-
|
|
966
|
Changes in non-cash operating working capital items
|
|
22,688
|
|
2,858
|
Net cash used in
operating activities
|
|
(12,446)
|
|
(10,891)
|
|
|
|
|
|
Financing
|
|
|
|
|
Proceeds from issuance of common shares
|
|
14,376
|
|
45,652
|
Proceeds from exercise of stock options
|
|
319
|
|
1,084
|
Proceeds from exercise of warrants
|
|
7,703
|
|
-
|
Payment of share issue costs
|
|
(1,832)
|
|
(3,486)
|
Issuance (repayment) of long-term debt
|
|
(1,938)
|
|
1,876
|
Increase in other long-term liabilities
|
|
72
|
|
171
|
Reverse acquisition, net of assets acquired
|
|
-
|
|
336
|
Net cash provided
by financing activities
|
|
18,700
|
|
45,633
|
|
|
|
|
|
Investing
|
|
|
|
|
Purchases of property, plant and equipment
|
|
(10,715)
|
|
(4,996)
|
Purchases of assets in process
|
|
(2,406)
|
|
(10,385)
|
Purchases of restricted investments
|
|
(236)
|
|
-
|
Acquisition of subsidiaries
|
|
1,054
|
|
-
|
Purchases of intangible assets
|
|
-
|
|
(5)
|
Net cash used in
investing activities
|
|
(12,303)
|
|
(15,386)
|
|
|
|
|
|
Net cash inflow
(outflow)
|
|
(6,049)
|
|
19,356
|
Cash and cash
equivalents, beginning of period
|
|
21,446
|
|
2,090
|
Cash and cash
equivalents, end of period
|
$
|
15,397
|
$
|
21,446
|
|
|
|
|
|
Unaudited Non-GAAP
Measure (In CDN$000's, except gram amounts)
|
|
Three Months
Ended
|
|
Year
Ended
|
Adjusted Product
Contribution1
|
|
March 31,
2016
|
|
March 31,
2016
|
|
|
|
|
|
Weighed average
cost per gram
|
$
|
2.69
|
$
|
2.69
|
Grams sold in the
period
|
|
700,395
|
|
1,696,440
|
|
|
|
|
|
Revenue
|
$
|
5,042
|
$
|
12,699
|
Adjusted cost
of sales2
|
|
(1,884)
|
|
(4,563)
|
Adjusted Product
Contribution
|
$
|
3,158
|
$
|
8,136
|
Adjusted Product
Contribution percentage of sales
|
|
62.6%
|
|
64.1%
|
|
|
|
|
|
As compared to the
Gross Margin per IFRS:
|
|
|
|
|
Gross margin,
including the unrealized gain on changes in fair value of
biological assets as reported on the Statements of Comprehensive
Loss
|
$
|
2,688
|
$
|
18,986
|
Gross
margin percentage of sales, including the unrealized gain on
changes in fair value of biological assets as reported on the
Statement of Comprehensive Loss
|
|
53.3%
|
|
149.5%
|
|
|
|
|
|
Notes:
|
|
|
|
|
1 The Adjusted
Product Contribution removes the fair value measurements required
under IFRS and recognizes the cost of sales based on the
weighted average cost per gram to produce and sell product in the
period.
|
2 Based on the
weighted average of cost per gram from seed to sale of $2.69 per
gram in both the fourth quarter and for the year and applied to the
number of grams sold in the period.
|
SOURCE Canopy Growth Corporation